Mylan NV has reached a tentative agreement to pay US$30 million to resolve a probe by the U.S. Securities and Exchange Commission related to its emergency allergy shot EpiPen, which became the center of a firestorm over price increases.
Mylan reaches US$30 million settlement in SEC’s EpiPen probe
